- Full name: 1-Methylnicotinamide chloride
- CAS: 1005-24-9
- Origin: Endogenous NAD+ metabolite (liver NNMT activity)
- Primary research: Vascular protection, prostacyclin synthesis, anti-inflammation
- Key researchers: Chlopicki et al. (Jagiellonian University, Krakow)
- Format: Oral capsule (60 mg) — stable, no reconstitution
01 What Is 1-MNA?
1-Methylnicotinamide (1-MNA) is an endogenous metabolite produced in the liver when nicotinamide N-methyltransferase (NNMT) adds a methyl group to nicotinamide (niacinamide). For decades it was viewed as merely a urinary excretion product — the "end of the line" for nicotinamide metabolism. Polish researchers, particularly Chlopicki's group at Jagiellonian University, systematically characterised its biological activity and identified it as a vascular protective and anti-inflammatory compound.
1-MNA occupies a unique niche in the NAD+ research space: it is downstream of NAD+ synthesis rather than upstream, which means its biological effects are not dependent on raising NAD+ levels and cannot be replicated by NMN or NR supplementation. It represents a distinct and underexplored branch of nicotinamide metabolism.
02 Position in the NAD+ Metabolic Pathway
The NAD+ salvage pathway in the liver proceeds:
- Tryptophan → Nicotinic acid (de novo synthesis via kynurenine pathway)
- Nicotinamide (NAM) ← Released from NAD+ by sirtuins and PARPs
- NAM → NMN (via NAMPT) → NAD+ (primary salvage route)
- NAM → 1-MNA (via NNMT) → eliminated in urine (methylation shunt)
NNMT activity diverts nicotinamide away from NAD+ synthesis toward 1-MNA production. High NNMT activity reduces intracellular NAD+ and SAM (S-adenosylmethionine) — the methyl donor consumed in the reaction. This has led to interest in NNMT inhibitors (like 5-Amino-1MQ) as a strategy to raise NAD+ by blocking the 1-MNA shunt. Conversely, supplementing 1-MNA directly delivers the metabolite without affecting upstream NAD+ levels.
03 Anti-Inflammatory Mechanism — Prostacyclin Pathway
1-MNA's primary characterised mechanism is upregulation of prostacyclin (PGI2) synthesis in vascular endothelial cells. Prostacyclin is a short-lived eicosanoid produced by COX-1/COX-2 from arachidonic acid — it acts as a potent vasodilator and inhibitor of platelet aggregation, counterbalancing the prothrombotic effects of thromboxane A2 (TXA2).
In Chlopicki's preclinical models:
- 1-MNA increased urinary 6-keto-PGF1α (stable prostacyclin metabolite) in a dose-dependent manner
- COX-2 inhibitor pretreatment blocked 1-MNA's vascular effects — confirming COX-2 dependence
- 1-MNA reduced neutrophil adhesion to endothelial cells in intravital microscopy studies
- NF-κB nuclear translocation and downstream inflammatory gene expression were attenuated
An additional observation: 1-MNA inhibits SIRT1 deacetylase activity in some models. Given NAD+'s role in activating sirtuins, this apparently paradoxical finding suggests 1-MNA's biology is genuinely distinct from NAD+ — not a downstream expression of it.
04 Vascular Research Findings
Published preclinical data from Jagiellonian University (2008–2023) demonstrates consistent vascular protective effects of 1-MNA in rodent models:
- Atherosclerosis: Reduced aortic plaque area in ApoE-/- mice supplemented with 1-MNA
- Endothelial function: Improved acetylcholine-induced vasodilation in mesenteric arteries of hypertensive rats
- Platelet aggregation: Reduced ex vivo ADP-induced platelet aggregation
- Microvascular inflammation: Reduced leukocyte rolling and adhesion in LPS-challenged mesenteric microcirculation
- Thrombosis model: Extended time-to-occlusion in ferric chloride-induced thrombosis model
Human data is limited to observational studies showing inverse correlations between plasma 1-MNA and cardiovascular risk markers. No randomised controlled clinical trial data exists as of 2026.
05 1-MNA vs NAD+, NMN, and NR
| Property | 1-MNA | NMN | NR | NAD+ |
|---|---|---|---|---|
| Position in pathway | Downstream (end product) | Upstream (NAD+ precursor) | Upstream (NAD+ precursor) | Central cofactor |
| Raises intracellular NAD+ | No | Yes | Yes | Yes |
| Prostacyclin upregulation | Yes (primary effect) | Not described | Not described | Not described |
| Sirtuin activation | Inhibits SIRT1 (reported) | Activates via NAD+ | Activates via NAD+ | Substrate for SIRT1-7 |
| Research format | Oral capsule | Capsule/powder | Capsule/powder | IV/capsule |
06 Frequently Asked Questions
What is 1-MNA (1-Methylnicotinamide)?
1-Methylnicotinamide (1-MNA) is an endogenous metabolite of nicotinamide (niacinamide), produced in the liver via methylation of nicotinamide by nicotinamide N-methyltransferase (NNMT). It was long considered merely a urinary excretion product of NAD+ metabolism, but research primarily from Polish groups (Brzozowski, Chlopicki) identified it as a biologically active compound with vascular protective and anti-inflammatory properties. It is distinct from NAD+, NMN, and NR despite sharing the nicotinamide scaffold.
How does 1-MNA differ from NAD+ and NMN?
NAD+ is the primary redox cofactor and sirtuin activator. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that raise intracellular NAD+ levels. 1-MNA sits downstream of nicotinamide in the NAD+ salvage pathway — it is a methylation endpoint product, not a precursor. Its biological activity appears to be largely NAD+-independent, acting instead on prostacyclin synthesis and inflammatory pathways via mechanisms that do not require conversion back to NAD+.
What is 1-MNA's mechanism of anti-inflammatory action?
1-MNA's primary described mechanism is upregulation of prostacyclin (PGI2) synthesis via COX-1/COX-2 pathways in endothelial cells. Prostacyclin is a vasodilatory, anti-aggregatory eicosanoid that counterbalances thromboxane A2. In rodent models, 1-MNA increased urinary 6-keto-PGF1α (stable prostacyclin metabolite), reduced neutrophil rolling and adhesion, and attenuated NF-κB-mediated inflammatory gene expression. It also inhibits sirtuin 1 (SIRT1) activity — a paradoxical finding given NAD+'s role in SIRT1 activation — which may contribute to its distinct biology.
What vascular research has been done with 1-MNA?
Polish clinical and preclinical data from Chlopicki's group (Jagiellonian University) is the primary body of 1-MNA research. In rodent models: 1-MNA reduced atherosclerotic lesion area, improved endothelial function (acetylcholine-induced vasodilation), reduced platelet aggregation ex vivo, and attenuated LPS-induced microvascular inflammation. Human observational data shows serum 1-MNA correlates inversely with cardiovascular risk markers. No large RCT data exists as of 2026.
Is 1-MNA the same as Niacinamide?
No. Niacinamide (nicotinamide) is the starting substrate. NNMT (nicotinamide N-methyltransferase) adds a methyl group to nicotinamide to produce 1-MNA — a structurally distinct compound with different biological properties. Niacinamide is used widely in skincare and as a B3 supplement; 1-MNA is its downstream metabolite with specific vascular and anti-inflammatory properties not shared by nicotinamide itself.
Related research: